|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
1994-11-22
|
|
pubmed:abstractText |
A reduction of peripheral CD4+ cell levels has been correlated with the onset of Pneumocystis carinii pneumonia in AIDS patients. Most in vivo drug discovery and development for P. carinii have been conducted in corticosteroid-treated rats. There is need for the development of new small animal models with more selective methods of immunosuppression. This study outlines a new mouse model in which specific depletion of the CD4+ T-lymphocyte population was achieved by subcutaneous injection of G.K1.5 hybridoma cells into C3HeB/FeJ mice. A significant reduction in splenic CD4+ cells was maintained over a 10-week period following a single injection of cells. Circulating anti-CD4+ antibody was detected throughout the 10-week period in hybridoma-injected mice, while circulating antibody was undetectable 4 weeks after repeated injection of purified monoclonal antibody. There was no significant increase in the CD8+ cell populations of the hybridoma-injected mice. P. carinii cysts increased in the lungs of CD4+ T-cell-depleted mice, with the number of cysts detected comparable to levels in dexamethasone-treated mice. High levels of cysts were detected when CD4+ cell populations in the spleen remained below 5% and decreased when CD4+ populations increased above the 5% level. In mice whose CD4+ population was not reduced below 5%, there was no significant increase in P. carinii cysts detected. This study presents a new mouse model with specific immunosuppression requiring a minimum of animal manipulation for use in discovery and development of potential new therapeutics for P. carinii pneumonia.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7927769-1548065,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7927769-1572137,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7927769-1666138,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7927769-1672543,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7927769-1673446,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7927769-1675629,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7927769-1967190,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7927769-2117637,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7927769-2139668,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7927769-2572556,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7927769-2642471,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7927769-2805792,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7927769-2968320,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7927769-301657,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7927769-313907,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7927769-3260765,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7927769-3871426,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7927769-4365115,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7927769-6195085,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7927769-6195255,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7927769-6415170,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7927769-8094045
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0019-9567
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
62
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4887-92
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:7927769-Animals,
pubmed-meshheading:7927769-CD4 Lymphocyte Count,
pubmed-meshheading:7927769-CD4-Positive T-Lymphocytes,
pubmed-meshheading:7927769-Dexamethasone,
pubmed-meshheading:7927769-Disease Models, Animal,
pubmed-meshheading:7927769-Hybridomas,
pubmed-meshheading:7927769-Immunocompromised Host,
pubmed-meshheading:7927769-Lymphocyte Depletion,
pubmed-meshheading:7927769-Male,
pubmed-meshheading:7927769-Mice,
pubmed-meshheading:7927769-Mice, Inbred C3H,
pubmed-meshheading:7927769-Pneumocystis,
pubmed-meshheading:7927769-Pneumonia, Pneumocystis
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Use of anti-CD4+ hybridoma cells to induce Pneumocystis carinii in mice.
|
|
pubmed:affiliation |
Merck Research Laboratories, Rahway, New Jersey 07065-0900.
|
|
pubmed:publicationType |
Journal Article
|
